Key Points
- Equillium insider Stephen Connelly sold 200,000 shares on June 4 at an average price of $3.16, for total proceeds of $632,000. After the sale, he still owned 793,000 shares, a 20.14% decrease in his stake.
- Connelly also sold another 30,975 shares on June 5 at an average price of $2.94, totaling about $91,067, adding to the recent insider selling activity.
- Equillium shares were down 7.3% and the company recently reported a quarterly loss of $0.06 per share, missing analyst estimates; despite this, Wall Street currently holds a Moderate Buy consensus with an average price target of $7.57.
Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 14,584 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $2.93, for a total value of $42,731.12. Following the completion of the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $183,376.98. This represents a 18.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christine Zedelmayer also recently made the following trade(s):
- On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The shares were sold at an average price of $2.80, for a total value of $240,833.60.
- On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The shares were sold at an average price of $2.70, for a total value of $26,516.70.
- On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The shares were sold at an average price of $2.50, for a total value of $300,780.00.
- On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total value of $362,438.00.
Equillium Price Performance
EQ stock opened at $2.94 on Friday. The firm has a market capitalization of $185.90 million, a P/E ratio of -9.19 and a beta of 1.77. The business's 50-day moving average is $2.20 and its two-hundred day moving average is $1.71. Equillium, Inc. has a 1 year low of $0.27 and a 1 year high of $3.45.
Equillium (NASDAQ:EQ - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). On average, analysts expect that Equillium, Inc. will post -0.24 EPS for the current year.
Wall Street Analysts Forecast Growth
EQ has been the topic of several research analyst reports. Roth Mkm reissued a "buy" rating and set a $12.00 target price on shares of Equillium in a research report on Thursday, May 28th. Stifel Nicolaus set a $5.00 target price on Equillium in a research report on Thursday, May 28th. Oppenheimer initiated coverage on Equillium in a research report on Thursday, April 23rd. They set an "outperform" rating and a $7.00 target price on the stock. B. Riley Financial initiated coverage on Equillium in a research report on Thursday, April 16th. They set a "buy" rating and a $6.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Equillium in a research report on Tuesday, April 7th. They set an "overweight" rating and a $10.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $7.57.
Get Our Latest Stock Analysis on Equillium
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in EQ. Janus Henderson Group PLC purchased a new position in Equillium during the 4th quarter worth approximately $9,057,000. ADAR1 Capital Management LLC purchased a new position in Equillium during the 3rd quarter worth approximately $7,951,000. Woodline Partners LP purchased a new position in Equillium during the 3rd quarter worth approximately $5,018,000. Aberdeen Group plc grew its stake in Equillium by 523.6% during the 4th quarter. Aberdeen Group plc now owns 2,366,688 shares of the company's stock worth $3,668,000 after buying an additional 1,987,162 shares during the last quarter. Finally, Eversept Partners LP purchased a new position in Equillium during the 1st quarter worth approximately $2,998,000. Hedge funds and other institutional investors own 27.05% of the company's stock.
Equillium Company Profile
(
Get Free Report)
Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.
Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
